Characterization of Treatment Resistant Depression Episodes in a Cohort of Patients from a US Commercial Claims Database
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
CONTEXT: Treatment Resistant Depression (TRD) is a significant and burdensome health concern. OBJECTIVE: To characterize, compare and understand the difference between TRD and non-TRD patients and episodes in respect of their episode duration, treatment patterns and healthcare resource utilization. DESIGN AND SETTING: Patients between 18 and 64 years with a new diagnosis of major depressive disorder (MDD) and without a previous or comorbid diagnosis of schizophrenia or bipolar disease were included from PharMetrics Integrated Database, a claims database of commercial insurers in the US. Episodes of these patients in which there were at least two distinct failed regimens involving antidepressants and antipsychotics were classified as TRD. PATIENTS: 82,742 MDD patients were included in the analysis; of these patients, 125,172 episodes were identified (47,654 of these were drug-treated episodes). MAIN OUTCOME MEASURES: Comparison between TRD and non-TRD episodes in terms of their duration, number and duration of lines of treatment, comorbidities, and medical resource utilization. RESULTS: Of the treated episodes, 6.6% (N = 3,134) met the criteria for TRD. The median time to an episode becoming TRD was approximately one year. The mean duration of a TRD episode was 1,004 days (vs. 452 days for a non-TRD episode). More than 75% of TRD episodes had at least four lines of therapy; half of the treatment regimens included a combination of drugs. Average hospitalization costs were higher for TRD than non-TRD episodes: $6,464 vs. $1,734, as were all other health care utilization costs. CONCLUSIONS: While this study was limited to relatively young and commercially covered patients, used a rigorous definition of TRD and did not analyze for cause or consequence, the results highlight high unmet medical need and burden of TRD on patients and health care resources.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988 · cited 2×
“Consequently, there are a number of people with symptoms commonly associated with depression or diagnosed as suffering from MDD, who do not receive depression-related drug or other forms of treatment [24].”
BackgroundResultRush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Cross-national epidemiology of DSM-IV major depressive episode
Bromet, E., Andrade, L. H., Hwang, I., Sampson, N. A., Alonso, J., de Girolamo, G., de Graaf, R., Demyttenaere, K., Hu, C., Iwata, N., et al. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-90 · Cited by 2,221
Depression and Type 2 Diabetes Over the Lifespan
Mezuk, B., Eaton, W. W., Albrecht, S., & Golden, S. H. (2008) · Diabetes Care · doi:10.2337/dc08-0985 · Cited by 1,558
The Economic Burden of Depression in the United States: How Did It Change Between 1990 and 2000?
Greenberg, P. E., Kessler, R. C., Birnbaum, H. G., Leong, S. A., Lowe, S. W., Berglund, P. A., & Corey-Lisle, P. K. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1211 · Cited by 1,280 · cited 1×
“In the US alone, the estimated direct and indirect cost amounted to $83 billion in 2000 [10], of which more than 50% of health expenditures were borne by the public sectors such as Medicaid, Medicare, state and local governments [11].”
BackgroundGaynes, B. N., Warden, D., Trivedi, M. H., Wisniewski, S. R., Fava, M., & Rush, A. J. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.11.1439 · Cited by 661
The Impact of Treatment-Resistant Depression on Health Care Utilization and Costs
Crown, W. H., Finkelstein, S., Berndt, E. R., Ling, D., Poret, A. W., Rush, A. J., & Russell, J. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1102 · Cited by 386
Economic implications of treatment-resistant depression among employees
Greenberg, P., Corey-Lisle, P. K., Birnbaum, H., Marynchenko, M., & Claxton, A. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422060-00003 · Cited by 113 · cited 2×
“Greenberg et al [26] have similarly shown higher incidence of comorbidities in TRD-likely employees as compared to MDD but TRD-unlikely employees in each of the 16 categories that they placed comorbidities in, e.”
BackgroundCorey-Lisle, P. K., Birnbaum, H. G., Greenberg, P. E., Marynchenko, M. B., & Claxton, A. J. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0810 · Cited by 84
Research works printed but not linked: 9
- Hirschfeld RMA, Weissman MM (2002) Risk Factors For Major Depression And Bipolar Disorder. Neuropsychopharmacology: The Fifth Generation of Progress Section 8: Chapter 70.
- DL Musselman, 1998, The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment, Arch Gen Psychiatry, 55, 580, 10.1001/archpsyc.55.7.580 · DOI · Paper page
- JI Ivanova, 2010, Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder, Curr Med Res Opin, 26, 2475, 10.1185/03007995.2010.517716 · DOI
- MB Keller, 2005, Issues in treatment-resistant depression, J Clin Psychiatry, 66, 5
- E Vieta, 2011, Therapeutic options in treatment-resistant depression, Ann Med, 43, 512, 10.3109/07853890.2011.583675 · DOI · Paper page
- TB Gibson, 2010, Cost burden of treatment resistance in patients with depression, Am J Manag Care, 16, 370
- D Souery, 1999, Treatment resistant depression: methodological overview and operational criteria, Eur Neuropsychopharmacol, 9, 83, 10.1016/S0924-977X(98)00004-2 · DOI · Paper page
- CB Nemeroff, 2007, Prevalence and management of treatment-resistant depression, J Clin Psychiatry, 68, 17
- NS Philip, 2010, Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era, Expert Opin Pharmacother, 11, 709, 10.1517/14656561003614781 · DOI
Cited by
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
“resistant depression may be marginally higher in women than in men (Kubitz et al. 2013).”
BackgroundZhdanava, M., Pilon, D., Ghelerter, I., Chow, W., Joshi, K., Lefebvre, P., & Sheehan, J. J. (2021) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.20m13699 · Cited by 523
Johnston, K. M., Powell, L. C., Anderson, I. M., Szabo, S., & Cline, S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.06.045 · Cited by 321
Fonagy, P., Rost, F., Carlyle, J., McPherson, S., Thomas, R., Pasco Fearon, R. M., Goldberg, D., & Taylor, D. (2015) · World Psychiatry · doi:10.1002/wps.20267 · Cited by 237
“Treatments for major depressive disorder generally have medium effect sizes (3), but observational studies and trials consistently report high rates of non-response (4,5), with 12 to 20% of depressed patients not benefitting even from multiple courses of treatment (6).”
BackgroundFonseca, R., Usmani, S. Z., Mehra, M., Slavcev, M., He, J., Cote, S., Lam, A., Ukropec, J., Maiese, E. M., Nair, S., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07503-y · Cited by 127
Self-citation
Metadata
- Authors
- Kubitz, N., Mehra, M., Potluri, R. C., Garg, N., & Cossrow, N.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-10-18
- Volume
- 8
- Issue
- 10
- Pages
- e76882
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2024075080
- Cited by
- 143
- References
- 9
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of Treatment Resistant Depression Episodes in a Cohort of Patients from a US Commercial Claims Database. https://app.cochat.ai/papers/10.1371/journal.pone.0076882
- The paper
- Kubitz, N., Mehra, M., Potluri, R. C., Garg, N., & Cossrow, N. (2013). Characterization of Treatment Resistant Depression Episodes in a Cohort of Patients from a US Commercial Claims Database. PLoS ONE. https://doi.org/10.1371/journal.pone.0076882
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.